Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 67
- Registration Number
- NCT00699504
- Locations
- 🇺🇸
Charles River Clinical Services NW, Tacoma, Washington, United States
Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Illinois Retina Associates
- Target Recruit Count
- 22
- Registration Number
- NCT00690313
- Locations
- 🇺🇸
Illinois Retina Associates, Harvey, Illinois, United States
Effects of Single Oral Dose Dapagliflozin QT Study
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00688493
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00686179
Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.
- Conditions
- Pelvic Inflammatory Disease
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 749
- Registration Number
- NCT00683865
A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2011-06-21
- Lead Sponsor
- CardioKine Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT00675701
- Locations
- 🇺🇸
Research Site 1, Austin, Texas, United States
Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00672399
- Locations
- 🇬🇧
Reseach Site, Derriford, Plymouth, United Kingdom
🇬🇧Research Site, Leeds, West Yorkshire, United Kingdom
Guanfacine Immediate-release Electrocardiogram Results (QTc) Study
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 83
- Registration Number
- NCT00672984
- Locations
- 🇺🇸
Charles River Clinical Services Northwest, Inc., Tacoma, Washington, United States
Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 192
- Registration Number
- NCT00668304
Bioequivalence of Eye Drops and Spray Administration of Vigamox
- Conditions
- Cataract
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Advanced Ophthalmic Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT00666042
- Locations
- 🇮🇱
Dept. of Ophthalmology, TAMC, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.